

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

FURTHER DELAY IN DESPATCH OF CIRCULAR IN RESPECT OF THE (1) MAJOR TRANSACTION IN RELATION TO THE CAPITAL INJECTION IN AND DEEMED DISPOSAL OF EQUITY INTEREST IN PENGBO (HAINAN) MEDICAL TECHNOLOGY CO., LTD#; AND (2) MAJOR TRANSACTION IN RELATION TO THE GRANT OF THE REPURCHASE RIGHTS

Reference is made to the announcement (the “**Announcement**”) of China Biotech Services Holdings Limited (the “**Company**”) dated 5 August 2024 in relation to, among others, the Capital Injection Agreement and the transactions contemplated thereunder (including, but not limited to, the Capital Injection and the Repurchase Rights) and the announcements dated 26 August 2024, 23 September 2024 and 4 October 2024 (the “**Delay Announcements**”, and together with the Announcement, the “**Announcements**”) in relation to the delay in despatch of the Circular. Unless otherwise defined, capitalised terms used herein shall have the same meaning as defined in the Announcements.

As set out in the Delay Announcements, the Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a waiver from strict compliance with Rule 19.41(a) of the GEM Listing Rules on the condition that the Circular would be despatched on or before Monday, 4 November 2024.

As more time is required for, among other things, finalising certain information for inclusion in the Circular, including but not limited to the statement of sufficiency of working capital and details regarding the amendments to the memorandum and articles of association of Dynamic Healthcare, the Company has applied to the Stock Exchange for a waiver from strict compliance with Rule 19.41(a) of the GEM Listing Rules for a further extension of the date of despatch of the Circular. Further announcement(s) will be made by the Company in respect of the application of the waiver and the expected date of despatch of the Circular.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

for identification purposes only

Hong Kong, 4 November 2024

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Liu Xiaolin (Chairman), Mr. He Xun, and Mr. Huang Song and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.